Intellia Therapeutics Plunges on Triple Blow of Clinical Setback and Financial Disappointment

Intellia Therapeutics shares experienced a severe downturn on Friday, plummeting 22.7% as investors reacted to a devastating combination of clinical, regulatory, and financial setbacks. The biotechnology firm faced a perfect storm of negative developments that shattered market confidence in one of its most promising experimental treatments.

The crisis began with Thursday’s third-quarter earnings report, which revealed a net loss of $101.3 million against modest revenue of $13.8 million. While these figures alone would have concerned investors, they were quickly overshadowed by more alarming news from the company’s clinical trial program.

In a devastating development for Intellia’s flagship program, a patient participating in the Phase 2 MAGNITUDE study of NTLA-2001 Read more...